Torrent Pharma to Acquire JB Chemicals; CCI Filing Reveals Strategic Merger in Formulations and CDMO Space
By Shishta Dutta | Updated at: Jan 9, 2026 02:00 PM IST
New Delhi, July 18 – Torrent Pharmaceuticals Ltd has officially notified the Competition Commission of India (CCI) of its intent to acquire J. B. Chemicals & Pharmaceuticals Ltd, followed by a merger, as per a filing under Regulation 13(2) of the 2024 Combinations Regulations.
According to the parties (Torrent Pharma and J B Chemicals), there are horizontal overlaps between their operations in a few pertinent areas for the production and distribution of FDFs in India.
Following the purchase of shares, JB Pharma will merge with Torrent, marking the second-largest transaction in the pharmaceutical industry’s history.
Torrent Pharmaceuticals Share Price Performance
Torrent Pharmaceuticals’ share price is currently showing positive momentum, trading at ₹3537.70 with a 0.94% increase. The stock peaked at ₹3,539.10 after opening at ₹3,512.30, which was higher than the previous day’s close of ₹3,504.60. The share has stayed low at ₹2,870.00 and reached a 52-week high of ₹3,590.70.
Strategic Transaction: Share Acquisition and Merger
The proposed transaction involves a two-stage combination:
- Acquisition of shareholding in JB Chemicals (the “Target”) by Torrent Pharmaceuticals (the “Acquirer”).
- Subsequent amalgamation of JB Chemicals with Torrent Pharma.
This deal qualifies as a notifiable combination under Section 5(a)(i)(A) of the Competition Act, 2002.
Deal Objectives: Entry into New Segments and CDMO Play
Torrent aims to leverage JB Chemicals’ growing domestic franchise in the chronic therapies segment and gain access to underpenetrated therapeutic categories like ophthalmology. The acquisition also offers Torrent entry into the contract development and manufacturing organisation (CDMO) sector, supporting long-term capital expansion.
The merger is expected to boost the combined entity’s product portfolio, platform capabilities, and market reach, allowing significant augmentation of their pharmaceutical offerings.
Business Overview of Parties
| Company | Business Focus |
|---|---|
| Torrent Pharmaceuticals | Manufacturing and sale of pharmaceutical formulations across multiple therapies |
| JB Chemicals | Manufacturing and marketing of formulations and APIs; provider of CDMO services |
Market Implications
The companies have acknowledged horizontal overlaps in their operations, particularly in the market for formulation drug products (FDFs) in India. The combination could prompt closer scrutiny on competitive effects within specific therapeutic areas.
About the Companies
Torrent Pharmaceuticals Ltd is the flagship pharma entity of the Torrent Group, publicly listed and widely recognised for its presence in cardiovascular, central nervous system, gastrointestinal, and diabetes segments.
JB Chemicals & Pharmaceuticals Ltd is a leading Indian pharma company with a legacy of branded generics, exports, and growing CDMO capabilities. It is also publicly listed and operates globally across emerging and regulated markets.
REF: https://www.cci.gov.in/images/summaryorders/en/summary1752666564.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
